Sinalização PI3K/Akt/mTOR
Os inibidores da sinalização PI3K/Akt/mTOR são compostos que têm como alvo as vias da fosfoinositídeo 3-quinase (PI3K), da quinase Akt e do alvo da rapamicina em mamíferos (mTOR). Essas vias são reguladores críticos do crescimento celular, sobrevivência, metabolismo e autofagia, tornando-os alvos-chave na pesquisa de câncer e distúrbios metabólicos. A inibição dessas vias pode ajudar a controlar o crescimento e a proliferação tumoral, oferecendo estratégias terapêuticas potenciais para vários tipos de câncer e outras doenças caracterizadas por sinalização celular desregulada. Na CymitQuimica, oferecemos uma ampla seleção de inibidores de alta qualidade de PI3K/Akt/mTOR para apoiar sua pesquisa em oncologia, sinalização celular e doenças metabólicas.
Subcategorias de "Sinalização PI3K/Akt/mTOR"
- AMPK(158 produtos)
- ATM/ATR(71 produtos)
- DNA-PK(51 produtos)
- EGFR(572 produtos)
- MELK(7 produtos)
- PDK(9 produtos)
- PI3K(242 produtos)
- S6 Quinase(9 produtos)
- gsk-3(112 produtos)
- mTOR(144 produtos)
Exibir 2 mais subcategorias
Foram encontrados 1038 produtos de "Sinalização PI3K/Akt/mTOR"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
Lumretuzumab
CAS:<p>Lumretuzumab (RG-7116) is a humanized anti-HER3 monoclonal antibody with antitumor activity.</p>Pureza:95.3% (SDS-PAGE); 96.4% (SEC-HPLC) - 95.3% (SDS-PAGE); 96.4% (SEC-HPLC)Cor e Forma:LiquidPhospho-Glycogen Synthase Peptide-2(substrate)
CAS:<p>Phospho-Glycogen Synthase Peptide-2 is a GSK-3 substrate, useful for serine kinase affinity purification.</p>Fórmula:C123H191N40O48PCor e Forma:SolidPeso molecular:3029.087EGFR-IN-76
CAS:<p>EGFR-IN-76 is a potent EGFR inhibitor.</p>Fórmula:C30H30ClFN6O2Pureza:97.02% - 97.72%Cor e Forma:SolidPeso molecular:561.05RMC-6272
CAS:<p>RMC-6272 (RM-006) is a bi-steric mTORC1 inhibitor with selective potency over mTORC2 and shows greater effects than Rapamycin on TSC2-deficient tumors.</p>Fórmula:C95H141FN6O27SCor e Forma:SolidPeso molecular:1850.25Matuzumab
CAS:<p>Matuzumab (EMD 72000) is a humanized monoclonal antibody targeting EGFR that can be used to study non-small cell lung cancer.</p>Pureza:95%Cor e Forma:LiquidPeso molecular:145.9 kDaGSK251
CAS:<p>GSK251 is a novel, orally bioavailable inhibitor of PI3Kδ, exhibiting high potency and selectivity, with a unique binding mode.</p>Fórmula:C29H37FN6O4SPureza:99.8%Cor e Forma:SolidPeso molecular:584.71PX-13-17OH
CAS:<p>PX-13-17OH has a wide range of applications in life science related research.</p>Fórmula:C29H42N2O8Cor e Forma:SolidPeso molecular:546.65KR-27370
<p>KR-27370 (compound 7f) is an antiviral agent and a selective PI4KIIIβ/PI4KIIIα inhibitor, with IC50 values of 3.1 nM and 15.8 nM, respectively. It exhibits inhibitory activity against human rhinovirus (hRV), Coxsackievirus, and other enteroviruses.</p>Fórmula:C27H27N3O6S2Peso molecular:553.13413Gefitinib N-oxide hydrochloride
<p>Gefitinib N-oxide hydrochloride is an N-oxide of EGFR inhibitor Gefitinib with IC50 of 2-37 nM.</p>Fórmula:C22H24ClFN4O41·5HClCor e Forma:SolidPeso molecular:517.59PI3K-IN-19 hydrochloride
CAS:<p>PI3K-IN-19 hydrochloride (WO2017153220, step 5) acts as a phosphatidylinositol-3-kinase (PI3K) inhibitor.</p>Fórmula:C23H27ClN8O5Cor e Forma:SolidPeso molecular:530.97GSK3β Inhibitor XI
CAS:<p>GSK3β Inhibitor XI has GSK3β inhibitory effect.</p>Fórmula:C18H15N5O3Cor e Forma:SolidPeso molecular:349.35PF-06465603
CAS:<p>PF-06465603 is a metabolite of PF-04691502, a highly potent and selective ATP competitive kinase inhibitor of class 1 PI3Ks and mTOR.</p>Fórmula:C22H25N5O5Cor e Forma:SolidPeso molecular:439.46GSK-3β inhibitor 1
CAS:<p>GSK-3β inhibitor 1 is an inhibitor of GSK-3β( IC50 of 4.9 nM) and demonstrates high antidiabetic efficacy.</p>Fórmula:C14H10N2OPureza:99.40%Cor e Forma:SolidPeso molecular:222.24GSK3-IN-4
CAS:<p>GSK3-IN-4 is a GSK-3 inhibitor with IC50 of 0.101-1 μM of GSK-3α and GSK-3β in Calipe Assay.</p>Fórmula:C18H20N4OPureza:98.33%Cor e Forma:SoildPeso molecular:308.38Zenocutuzumab
CAS:<p>Zenocutuzumab (MCLA-128) is a humanized antibody targeting HER2, used for research on tumors driven by NRG1 gene rearrangement.</p>Pureza:97%Cor e Forma:LiquidJYQ-164
<p>JYQ-164 is a small molecule inhibitor targeting human Parkinson's disease protein 7 (PARK7/DJ-1). It functions by covalently and selectively targeting the critical residue Cys106 of PARK7, exhibiting an IC50 of 21 nM. JYQ-164 demonstrates five times greater inhibitory potency against PARK7 compared to the previously reported inhibitor, JYQ-88. It is applicable for research in Parkinson's disease and cancer.</p>Fórmula:C23H26N6O5S2Peso molecular:530.14061PRMT5/EGFR-IN-1
<p>PRMT5/EGFR-IN-1 (Compound 10p) is an orally active dual inhibitor targeting PRMT5 and EGFR, with IC50 values of 15.47 μM and 19.31 μM, respectively. It demonstrates antiproliferative activity against the A549, MCF7, HeLa, and MDA-MB-231 cell lines. This compound also exhibits favorable pharmacokinetic (PK) and pharmacodynamic (PD) properties in vivo and significantly inhibits the growth of MCF7 orthotopic xenograft tumors.</p>Fórmula:C27H22F6N2O2Peso molecular:520.15855EGFR-IN-95
<p>EGFR-IN-95 is a derivative of 2,4-diaminonicotinamide. It effectively inhibits the activity of EGFRdel19/T790M/C797S and L858R/T790M/C797S.</p>Fórmula:C23H28F2N8O3SPeso molecular:534.19731Multi-target kinase inhibitor 4
<p>Multi-target kinase inhibitor 4 (Compound 2) is a PI3K/DNA-PK inhibitor and a potent chemosensitizer that enhances the number of DNA double-strand breaks induced by Doxorubicin. It serves as an effective multidrug resistance (MDR) inhibitor, demonstrating inhibitory activity against P-glycoprotein (P-gp) mediated drug efflux. Multi-target kinase inhibitor 4 can be encapsulated in PEG-coated lipid nanoparticles.</p>Cor e Forma:Odour SolidEGFR-IN-116
<p>EGFR-IN-116 (compound 14D) is an antineoplastic agent. It exhibits an IC50 value of 0.103 μM for EGFR, 0.069 μM for VEGFR-2, and 19.74 μM for Topo II.</p>Fórmula:C26H22N6O2SPeso molecular:482.1525PROTAC EGFR degrader 11
CAS:<p>PROTAC EGFR degrader 11 (Compound B71) is a PROTAC degrader targeting the epidermal growth factor receptor (EGFR), with a DC50 of less than 100 nM. It binds to CRBN-DDB1 with a Ki of 36 nM. This compound effectively degrades EGFR, focal adhesion kinase (FAK), and RSK1, and inhibits the proliferation of BaF3 wild-type and EGFR mutant cells, exhibiting an IC50 of less than 100 nM.</p>Fórmula:C49H64ClFN10O7SCor e Forma:SolidPeso molecular:991.61ZM 449829
CAS:<p>ZM 449829: Selective JAK3 inhibitor, binds to ATP site. pIC50: 6.8 for JAK3, others < 5.0.</p>Fórmula:C13H10OPureza:98%Cor e Forma:SolidPeso molecular:182.222EGFR-IN-128
<p>EGFR-IN-128 (compound 28) is a potent and selective molecule targeting wild-type EGFREx20Ins, demonstrating therapeutic efficacy across various human xenograft models and capable of penetrating the blood-brain barrier in preclinical species.</p>Fórmula:C27H20N4OCor e Forma:SolidPeso molecular:416.47Kinase Inhibitor Library
<p>A unique collection of 2720 kinase inhibitors/regulators for high throughput screening and high content screening for drug discovery in kinase related diseases;</p>Cor e Forma:Odour SolidCN009543V
CAS:<p>CN009543V is an enhancer of tyrosine phosphorylation of EGFR via downstream signaling pathways.</p>Fórmula:C12H12N4O6SCor e Forma:SolidPeso molecular:340.31DNA Damage & Repair Compound Library
<p>A unique collection of xnum DNA Damage &amp; Repair related compounds for high throughput screening (HTS) and high content screening (HCS);</p>Cor e Forma:Odour SolidZLN 024 hydrochloride
CAS:<p>ZLN 024 hydrochloride is an AMPK allosteric activator and stimulates the inactive α1 subunit truncations α1 (1-394) and α1 (1-335) but not α1 (1-312).</p>Fórmula:C13H14BrClN2OSPureza:98.541%Cor e Forma:SolidPeso molecular:361.68HER2-IN-13
CAS:<p>HER2-IN-13 (Compound 33) serves as an effective HER2 inhibitor, exhibiting an IC50 value of 8 nM, and additionally demonstrates inhibition of wt-EGFR with an</p>Fórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96ALKBH1-IN-3 prodrug
<p>ALKBH1-IN-4 prodrug (Compound 29E) is a prodrug of an inhibitor targeting the DNA N6-methyladenine demethylase enzyme ALKBH1. It works by significantly increasing the cellular abundance of 6mA and enhancing the AMPK signaling pathway, which suppresses the vitality of gastric cancer cells. ALKBH1-IN-4 prodrug displays excellent cellular activity and favorable metabolic exposure in vivo, making it a promising candidate for research in gastric cancer-related areas.</p>Cor e Forma:Odour SolidPI3Kδ-IN-9
CAS:<p>PI3Kδ-IN-9 is a selective PI3Kδ inhibitor with an IC 50 value of 3.8 nM.</p>Fórmula:C24H26FN9OCor e Forma:SolidPeso molecular:475.532PI3-Kinase α Inhibitor 2 (hydrochloride)
CAS:<p>PI3-Kinase α Inhibitor 2 (hydrochloride) is a PI3-Kinase α inhibitor.</p>Fórmula:C16H17Cl2N3O2SCor e Forma:SolidPeso molecular:386.3Simotinib hydrochloride
CAS:<p>Simotinib hydrochloride: selective oral EGFR inhibitor, IC50 19.9 nM, potent anticancer agent.</p>Fórmula:C25H27Cl2FN4O4Cor e Forma:SolidPeso molecular:537.41EGFR-IN-42
<p>EGFR-IN-42 (17b) is a potent EGFR inhibitor with nanomolar efficacy, merging tamoxifen/endoxifen and gefitinib, exhibiting enhanced anti-cancer action.</p>Fórmula:C49H53ClFN5O5Cor e Forma:SolidPeso molecular:846.436-Me-ATP
CAS:<p>6-Me-ATP, a modified ATP, binds well to GSK3 and donates phosphate for GSK3β phosphorylation.</p>Fórmula:C11H18N5O13P3Cor e Forma:SolidPeso molecular:521.212B-(SP)
CAS:<p>Selective phosphopeptide substrate for glycogen synthase kinase-3 (GSK-3)</p>Fórmula:C71H123N26O29PPureza:98%Cor e Forma:SolidPeso molecular:1835.87Istiratumab
CAS:<p>Istiratumab (M-6495) is a bispecific antibody against IGF-1R/ErbB3 for cancer research, promoting receptor degradation.</p>Cor e Forma:LiquidPhosphatidylinositol 4,5-bisphosphate
CAS:<p>Phosphatidylinositol 4,5-bisphosphate, a cell membrane phospholipid, is a PLC and PI3K substrate and a messenger.</p>Fórmula:C47H85O19P3Cor e Forma:SolidPeso molecular:1047.09AG-1478 hydrochloride
CAS:<p>AG1478 HCl is an epidermal growth factor receptor protein inhibitor.</p>Fórmula:C16H15Cl2N3O2Cor e Forma:SolidPeso molecular:352.21HER2-IN-14
CAS:<p>HER2-IN-14 (Compound 34) is a potent inhibitor of HER2, achieving an inhibitory concentration (IC50) of 18 nM.</p>Fórmula:C26H23ClF2N8O3Cor e Forma:SolidPeso molecular:568.96PI3Kγ inhibitor 5
CAS:<p>PI3Kγ inhibitor 5 is a potent inhibitor of phosphoinositide 3-kinase γ (PI3Kγ), exhibiting an exceptional IC50 value of 34 nM.</p>Fórmula:C28H32F2N6O4Cor e Forma:SolidPeso molecular:554.599(3S)-GSK-F1
CAS:<p>(3S)-GSK-F1 is a selective small molecule inhibitor of Type III Phosphatidylinositol 4‑Kinase Alpha (PI4KIIIα), pIC50=8.3.</p>Fórmula:C27H18F5N5O4SPureza:99.04%Cor e Forma:SoildPeso molecular:603.52DSPE-PEG2000-GE11
<p>DSPE-PEG2000-GE11 is a PEG compound composed of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells that overexpress EGFR. DSPE-PEG2000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidQL-IX-55
CAS:<p>QL-IX-55 has a wide range of applications in life science related research.</p>Fórmula:C24H14F4N4OCor e Forma:SolidPeso molecular:450.39DP-C-4
<p>DP-C-4 is a Cereblon-based dual PROTAC for simultaneous degradation of EGFR and PARP[1].</p>Cor e Forma:LiquidOK2
<p>OK2, a specific inhibitor of the CCN2/EGFR interaction, effectively disrupts this interaction by binding to the CT domain of CCN2.</p>Fórmula:C42H62N14O9Pureza:98%Cor e Forma:SolidPeso molecular:907.03Duligotuzumab
CAS:<p>Duligotuzumab is a dual-targeting anti-EGFR/HER3 mAb that blocks signaling and induces ADCC for tumors with poor prognosis.</p>Pureza:95% - 95%Cor e Forma:LiquidAMX-818
<p>AMX-818 is a conditionally activated, masked T cell engager (TCE) that targets HER2. It demonstrates potent T cell cytotoxicity against HER2-positive tumor cell lines and can induce tumor regression in vivo. AMX-818 holds promise for research into HER2-positive solid tumors.</p>Cor e Forma:Odour LiquidCetuximab (PBS)
<p>Cetuximab (PBS) is a human IgG1 monoclonal antibody that inhibits the epidermal growth factor receptor (EGFR), with a dissociation constant (Kd) of 0.201 nM for EGFR as measured by the SPR method. It exhibits potent antitumor activity.</p>Cor e Forma:Odour LiquidCYH33
CAS:<p>CYH33: Oral PI3Kα inhibitor, IC50=5.9 nMα/598 nMβ/78.7 nMδ/225 nMγ; blocks Akt, ERK; causes G1 arrest in breast/lung cancer; effective on solid tumors.</p>Fórmula:C24H29F3N8O5SCor e Forma:SolidPeso molecular:598.6Depatuxizumab MMAF
<p>Depatuxizumab-MMAF, an antibody-drug conjugate (ADC), comprises an EGFR-targeted antibody linked to McMMAF and is utilized in glioblastoma research.</p>Cor e Forma:LiquidPeso molecular:148.24 kDaDSPE-PEG5000-GE11
<p>DSPE-PEG5000-GE11 is a PEG compound composed of DSPE and the EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells with EGFR overexpression. DSPE-PEG5000-GE11 is utilized in drug delivery.</p>Cor e Forma:Odour SolidMS9427
CAS:<p>MS9427: PROTAC EGFR degrader, 7.1 nM (WT), 4.3 nM (L858R); targets mutant via UPS and autophagy; inhibits NSCLC cell growth; anticancer research.</p>Fórmula:C48H58ClFN8O12Cor e Forma:SolidPeso molecular:993.47EGFR T790M/L858R-IN-9
<p>EGFRT790M/L858R-IN-9 (Compound 8) is an inhibitor targeting the EGFR-L858R/T790M mutations. It effectively inhibits the phosphorylation of the EGFR-L858R/T790M mutant kinase, demonstrating an IC50 value of 0.0064 µM. Additionally, EGFRT790M/L858R-IN-9 can suppress the proliferation of non-small cell lung cancer (NSCLC) cells, making it useful for cancer research.</p>Fórmula:C26H27N7O3SCor e Forma:SolidPeso molecular:517.603HL-8
CAS:<p>HL-8, a PROTAC targeting PI3K, degrades it fully at 10 μM in 8h, useful in cancer research.</p>Fórmula:C57H59F2N11O9S2Cor e Forma:SolidPeso molecular:1144.27GSK3β/mTOR modulator 1
<p>GSK3β/mTOR modulator 1 (derivative 2) is an agent that modulates the GSK3β/mTOR signaling pathway. It is applicable in research related to acute lung injury (ALI) and inflammation.</p>Fórmula:C19H28O5Cor e Forma:SolidPeso molecular:336.19367Anti-ERBB3/HER3 (29Z6)
<p>Anti-ERBB3/HER3 (29Z6) is an antibody inhibitor targeting human ERBB3/HER3.</p>Cor e Forma:Odour LiquidEGFR-IN-22
CAS:<p>EGFR-IN-22: potent for EGFR (IC50: 4.91 nM) & L858R/T790M/C797S mutation (IC50: 0.54 nM).</p>Fórmula:C38H47BrFN10O2PCor e Forma:SolidPeso molecular:805.72JBJ-09-063 TFA
<p>JBJ-09-063 TFA, an EGFR inhibitor selective for EGFR mutations, IC50s: 0.147-0.396 nM, blocks EGFR/Akt/ERK signaling, for EGFR-mutant lung cancer research.</p>Fórmula:C33H30F4N4O5SCor e Forma:SolidPeso molecular:670.67Varlitinib
CAS:<p>Varlitinib (ASLAN001) is a potent, reversible, small molecule pan-EGFR inhibitor with IC50s of 7, 2, 4 nM for HER1, HER2 and HER4, respectively.</p>Fórmula:C22H19ClN6O2SPureza:99.7%Cor e Forma:SolidPeso molecular:466.94EGFR/VEGFR2-IN-5
<p>EGFR/VEGFR2-IN-5 (Compound 14) is an orally active dual inhibitor of EGFR and VEGFR2, exhibiting an IC50 value of 1.15 µM for VEGFR2 and 0.28 µM for EGFRT790M. This compound demonstrates significant anticancer activity.</p>Fórmula:C17H15N7O5SCor e Forma:SolidPeso molecular:429.41DS06652923
<p>DS06652923 is an orally active inhibitor targeting EGFR triple mutations. It exhibits growth-inhibitory effects on Ba/F3EGFRdel19/T90M/C795S cells, with a GI50 value of 9.4 nM. Additionally, DS06652923 induces tumor regression in the Ba/F3 syngeneic transplantation model.</p>Cor e Forma:Odour SolidDA-143
<p>DA-143 is a selective inhibitor of DNA-PKcs (IC50: 2.5 nM), demonstrating disparate inhibitory effects on mTOR, PI3KΔ, and ATM, with IC50 values of 280 nM, 106 nM, and 6,594 nM, respectively. This compound effectively blocks the phosphorylation of DNA-PKcs substrates and enhances the sensitivity of cancer cells to doxorubicin.</p>Cor e Forma:Odour SolidPROTAC EGFR degrader 2
<p>Potent PROTAC EGFR degrader 2; IC50: 4.0 nM, DC50: 36.51 nM; inhibits cell growth; for NTR-responsive synthesis.</p>Fórmula:C58H72ClFN12O8SCor e Forma:SolidPeso molecular:1151.78ALKBH1-IN-3
<p>ALKBH1-IN-3 is an effective inhibitor of the DNA N6-methyladenosine (6mA) demethylase ALKBH1. This compound enhances the abundance of 6mA in gastric cancer cell lines HGC27 and AGS, simultaneously inhibiting cell viability and upregulating the AMP-activated protein kinase (AMPK) signaling pathway. ALKBH1-IN-3 holds potential for use in cancer research, including studies on gastric cancer.</p>Cor e Forma:Odour SolidARRY-380 (analog )
CAS:<p>ARRY-380 analog (HER2-Inhibitor-1) is a potent and selective HER2 inhibitor.</p>Fórmula:C29H27N7O4SPureza:99.82%Cor e Forma:SolidPeso molecular:569.63FAP-PI3KI1
CAS:<p>FAP-PI3KI1: A FAP-targeted PI3K inhibitor reducing collagen synthesis in human IPF cells.</p>Fórmula:C52H48F4N10O12S3Cor e Forma:SolidPeso molecular:1177.19EGFR-IN-124
<p>EGFR-IN-124 (compound 10A) is an EGFR inhibitor with an IC50 value of 0.54 μM, utilized in cancer research.</p>Cor e Forma:Odour SolidEGFR-IN-127
<p>EGFR-IN-127 is an ATP-competitive inhibitor targeting EGFR, with IC50 values of 136.3 nM for EGFRdel19 and 161.2 nM for EGFRdel19/T790M/C797S. This compound holds potential for the study of non-small cell lung cancer (NSCLC).</p>Cor e Forma:Odour SolidIC 86621
CAS:<p>IC 86621: DNA-PK ATP-competitive inhibitor, IC50 120 nM, enhances DSB antitumor effects, EC50 68 µM for repair.</p>Fórmula:C12H15NO3Pureza:99.68%Cor e Forma:SolidPeso molecular:221.25GSK-3β inhibitor 21
<p>GSK-3β Inhibitor21 (compound 44) is an ATP-competitive inhibitor of GSK-3β with an IC50 value of 6.06 µM, characterized by its ability to inhibit tau phosphorylation and prevent amyloid protein aggregation. This compound is utilized in the research of Alzheimer's disease.</p>Cor e Forma:Odour SolidCetuximab MMAE
<p>Cetuximab-MMAE, an antibody-drug conjugate (ADC), combines an EGFR-targeting antibody with Monomethyl auristatin E (MMAE) to investigate colorectal and head and neck cancers.</p>Cor e Forma:LiquidPeso molecular:150 kDaUmbralisib R-enantiomer
CAS:<p>Umbralisib R-enantiomer (RP5264 R-enantiomer) is a delta inhibitor of PI3K and a less active enantiomer of TGR-1202.</p>Fórmula:C31H24F3N5O3Pureza:97.34%Cor e Forma:SolidPeso molecular:571.55GSK-3β inhibitor 24
<p>GSK-3β inhibitor24 (Compound 41) is a potent GSK-3β inhibitor with an IC50 of 0.22 nM. It increases GSK-3β phosphorylation at the Ser9 site in a dose-dependent manner and inhibits tau protein hyperphosphorylation by reducing the abundance of p-tau-Ser396. The compound upregulates β-catenin and neurogenesis-related markers (GAP43 and MAP-2), demonstrating significant anti-Alzheimer's disease (AD) activity.</p>Fórmula:C26H18N4O3Cor e Forma:SolidPeso molecular:434.446HER2/neu (654-662) GP2
CAS:<p>Phage display selected Affibody ligands for HER2/neu from a protein library based on a 58-residue Staphylococcal protein A Z domain.</p>Fórmula:C42H77N9O11Pureza:98%Cor e Forma:SolidPeso molecular:884.11EGFR/PI3Kα-IN-1
<p>EGFR/PI3Kα-IN-1 (compound 30k), a dual EGFR/PI3Kα inhibitor, exhibits potent activity with IC 50 values of 3.6 nM (EGFRL858R/T790M) and 30 nM (PI3Kα). It effectively inhibits tumor cell proliferation and demonstrates significant anticancer activity.</p>Fórmula:C50H49N11O5SCor e Forma:SolidPeso molecular:916.06GSK-3β inhibitor 23
<p>GSK-3β inhibitor23 (Compound 11726169) is an inhibitor of glycogen synthase kinase 3 (GSK-3), effectively inhibiting GSK-3β and GSK-3α with IC50 values of 12.1 nM and 18.8 nM, respectively. It demonstrates antiviral activity against HIV1 and exhibits good metabolic stability in mouse and human liver microsomes and plasma, although it has poor permeability in Caco-2 cells, indicating potentially low oral bioavailability.</p>Fórmula:C18H13Cl2N5O2SCor e Forma:SolidPeso molecular:434.299Tephrosin
CAS:<p>Tephrosin induces degradation of of EGFR and ErbB2 by inducing internalization of the receptors, has potent antitumor activities.</p>Fórmula:C23H22O7Pureza:98%Cor e Forma:SolidPeso molecular:410.42MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate
CAS:<p>MC-Val-Cit-PAB-Amide-TLR7 agonist 4 Conjugate is a conjugate formed by linking MC-Val-Cit-PAB-Amide and TLR7 agonist 4, useful for cancer research.</p>Fórmula:C52H72N12O11Pureza:97.70%Cor e Forma:SolidPeso molecular:1041.2IBI-334
<p>IBI-334 is a bispecific antibody targeting both B7-H3 and EGFR. It features an EGFR arm responsible for signal blocking, connected to a modified B7-H3 arm that ensures optimal affinity and binding. The antibody is afucosylated to enhance its antibody-dependent cellular cytotoxicity (ADCC) effects. IBI-334 is widely applicable in EGFR-driven solid tumors.</p>Cor e Forma:Odour LiquidGSK-3β inhibitor 19
<p>GSK-3β Inhibitor 19 (compound 36) is an inhibitor of GSK-3β with an IC50 value of 70 nM. It is applicable in research related to anti-inflammatory and Alzheimer's disease.</p>Fórmula:C15H12N4O2SCor e Forma:SolidPeso molecular:312.35YH32367
<p>YH32367 (ABL105) is a bispecific antibody targeting HER2 and 4-1BB. It induces the secretion of IFN-γ, resulting in the death of tumor cells when co-cultured with hPBMC and HER2-expressing tumor cells. YH32367 demonstrates notable antitumor activity.</p>Cor e Forma:Odour LiquidTimigutuzumab
CAS:<p>Timigutuzumab (GEXMab73) is a humanized monoclonal antibody designed to target ErbB2, showing potential application in cancer research [1].</p>Cor e Forma:LiquidAnticancer agent 271
<p>Anticanceragent 271 (compound 5C) exhibits antiproliferative activity against lung cancer (A549), colon cancer (Caco-2) cell lines, and human lung fibroblasts (WI38), with an IC50 value of 9.18 μM for A549 cells. This compound can downregulate PI3K and mTOR gene expression and is applicable in cancer research.</p>Cor e Forma:Odour SolidWAY-270360
CAS:<p>WAY-270360 (N-[4-(1H-benzimidazol-2-yl)phenyl]-2,4-dimethoxybenzamide) is a sirtuin modulator and an epidermal growth factor receptor (EGFR) inhibitor.</p>Fórmula:C22H19N3O3Pureza:98.05%Cor e Forma:SolidPeso molecular:373.4DSPE-PEG1000-GE11
<p>DSPE-PEG1000-GE11 is a PEG compound made up of DSPE and an EGFR-targeting peptide (GE11). GE11 is applicable for cancer cells overexpressing EGFR. DSPE-PEG1000-GE11 serves a role in drug delivery.</p>Cor e Forma:Odour SolidPX-866-17OH
CAS:<p>PX-866-17OH can be used in related research in the field of life sciences. Its product number is T36312 and CAS number is 1012327-63-7.</p>Fórmula:C29H37NO8Cor e Forma:SolidPeso molecular:527.61IHMT-PI3K-315
<p>IHMT-PI3K-315 (20e) serves as a potent, selective inhibitor of PI3Kγ/δ, exhibiting IC 50 values of 4.0 nM for PI3Kγ and 9.1 nM for PI3Kδ. Additionally, it demonstrates antitumor activity.</p>Fórmula:C22H20F2N6O4Cor e Forma:SolidPeso molecular:470.43Varlitinib Tosylate
CAS:<p>Varlitinib Tosylate is a selective and potent inhibitor of ErbB1(EGFR) and ErbB2(HER2).</p>Fórmula:C36H35ClN6O8S3Pureza:98%Cor e Forma:SolidPeso molecular:811.34RMC-4529
CAS:<p>RMC-4529 is a chemical compound that demonstrates potent inhibition, with an IC50 value of 1.0 nM, against p-4E-BP1-(T37/46) in mTOR kinase cellular assays.</p>Fórmula:C90H139N13O23Cor e Forma:SolidPeso molecular:1771.17Lyso-Monosialoganglioside GM3
CAS:<p>Lyso-Monosialoganglioside GM3 (Lyso-GM3) is an analog of Ganglioside GM3 with antitumor properties. It inhibits the increase in EGFR kinase activity induced by EGF in A431 epithelial cancer cells.</p>Fórmula:C41H74N2O20Cor e Forma:SolidPeso molecular:915.028GSK2292767 FA
<p>GSK2292767 FA: potent PI3Kδ inhibitor, pIC50=10.1, 500x selectivity, for respiratory research.</p>Fórmula:C25H30N6O7SPureza:99.52%Cor e Forma:SoildPeso molecular:558.61AZ14240475
<p>AZ14240475 is a potent, selective, brain-penetrant inhibitor of EGFREx20Ins mutants (EGFREx20Ins mutants) with a pIC50 of 7.6, playing a significant role in cancer research.</p>Fórmula:C23H15ClF2N6O2Cor e Forma:SolidPeso molecular:480.854EGFR-IN-148
<p>EGFR-IN-148 (compound 8c) is a potent EGFR inhibitor with an IC50 of 0.161 μM. It induces G1/S phase arrest and significantly enhances apoptosis in HepG2 cells.</p>Fórmula:C17H16N4O4SCor e Forma:SolidPeso molecular:372.398Inetetamab
<p>Inetetamab is a recombinant humanized antibody targeting HER2 receptor domain IV, with anticancer activity, inducing pyroptosis in lung adenocarcinoma.</p>Pureza:96.54% (SEC-HPLC) - 96.54% (SEC-HPLC)Cor e Forma:Odour LiquidPI3K-IN-22
CAS:<p>PI3K-IN-22 is a dual kinase inhibitor of PI3Kα and mTOR, with IC50s of 0.9 and 0.6 nM respectively. PI3K-IN-22 could be used in cancer.</p>Fórmula:C31H35F3N8O3Cor e Forma:SolidPeso molecular:624.66GW 583340
CAS:<p>GW 583340 is a potent and selective dual inhibitor of EGFR/ErbB2 tyrosine kinase with the advantage of oral dosability and antitumor effects.</p>Fórmula:C28H25ClFN5O3S2Pureza:98.68%Cor e Forma:SoildPeso molecular:598.11PI3Kα-IN-25
<p>PI3Kα-IN-25 (Compound Djh1) is a selective inhibitor of PI3Kα, suitable for research in triple-negative breast cancer.</p>Fórmula:C21H19ClN4O4Cor e Forma:SolidPeso molecular:426.853mTOR inhibitor 9f
CAS:<p>mTOR inhibitor 9f is a selective mTOR inhibitor with IC50 of 1.25nM and 82nM for mTOR and PI3Kα, respectively.</p>Fórmula:C25H23N5O2SPureza:99.18%Cor e Forma:SoildPeso molecular:457.55CZY43
<p>CZY43 is an HER3 degrader that effectively induces degradation of HER3 in breast cancer SKBR3 cells in a dose- and time-dependent manner. It efficiently inhibits HER3-dependent signaling and cancer cell growth, outperforming Bosutinib.</p>Fórmula:C42H53Cl2N5O3Cor e Forma:SolidPeso molecular:746.808RMC-4627
CAS:<p>RMC-4627 is a selective mTORC1 inhibitor that activates 4EBP1 and inhibits tumor growth.</p>Fórmula:C93H141N11O23Cor e Forma:SolidPeso molecular:1781.17
